疑似导管感染患者立即重新置入新导管与后续死亡率的关联:一项队列研究
该研究在中国一所大学医院32张床位的ICU中,纳入2009年1月至2021年4月因疑似导管相关血流感染拔除中心静脉导管的1238例患者,其中877例(70.8%)立即重新置入新导管,361例(29.2%)未立即重新置入。经倾向性评分匹配后的682例患者中,多变量、多水平校正后立即重新置入新导管与30天死亡率升高相关(HR 1.481;95%CI 1.028至2.134)。Kaplan-Meier分析显示匹配前(P=0.00096)和匹配后(P=0.018)立即重新置入新导管均与死亡风险相关,竞争风险分析证实了倾向性评分匹配分析的结果。作者认为需要大样本随机对照试验来确定疑似导管相关血流感染时中心静脉导管的最佳管理方案。
要点
- 因疑似导管相关血流感染拔除中心静脉导管后,立即重新置入新导管与30天死亡率升高相关(HR 1.481;95%CI 1.028至2.134)。
- 1238例因疑似导管相关血流感染拔除中心静脉导管的患者中,877例(70.8%)立即重新置入新导管,361例(29.2%)未立即重新置入。
- 倾向性评分匹配后682例患者中,Kaplan-Meier分析显示立即重新置入新导管与死亡风险相关(匹配前P=0.00096,匹配后P=0.018)。
- 疑似导管相关血流感染患者中,血流感染相关归因风险与其他感染相比30天死亡率无显著差异(HR 1.081;95%CI 0.964至1.213)。
- 作者认为需要大样本随机对照试验来确定疑似导管相关血流感染时中心静脉导管的最佳管理方案,因为立即重新置入新导管也可能与非感染性并发症相关。
适用人群与场景
- 中国一所大学医院32张床位ICU中,2009年1月至2021年4月因疑似导管相关血流感染拔除中心静脉导管的患者。
- 疑似导管相关血流感染通过导管尖端培养和临床症状识别。
诊断标准与关键阈值
- 疑似导管相关血流感染通过导管尖端培养和临床症状识别。
研究设计与关键结果
- 研究类型为倾向性评分匹配队列研究,纳入1238例因疑似导管相关血流感染拔除中心静脉导管的患者,其中877例(70.8%)立即重新置入新导管,361例(29.2%)未立即重新置入。
- 倾向性评分匹配后682例患者中,多变量、多水平校正后立即重新置入新导管与30天死亡率升高相关(HR 1.481;95%CI 1.028至2.134)。
- Kaplan-Meier分析显示立即重新置入新导管与死亡风险相关:匹配前P=0.00096,匹配后P=0.018。
- 竞争风险分析证实了倾向性评分匹配分析的结果。
- 疑似导管相关血流感染患者中,血流感染相关归因风险与其他感染相比30天死亡率无显著差异(HR 1.081;95%CI 0.964至1.213)。
证据类型、等级与局限
- 证据类型:队列研究(倾向性评分匹配)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在疑似导管相关血流感染患者中,立即重新置入新导管与延迟置入中心静脉导管或无中心静脉导管相比,与更高的30天死亡率相关。
- 作者认为需要大样本随机对照试验来确定疑似导管相关血流感染时中心静脉导管的最佳管理方案,因为立即重新置入新导管也可能与非感染性并发症相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Central venous catheter (CVC) insertion complications are a prevalent and important problem in the intensive care unit (ICU), and source control by immediate catheter removal is considered urgent in patients with septic shock suspected to be caused by catheter-related bloodstream infection (CRBSI). We sought to determine the impact of immediate reinsertion of a new catheter (IRINC) on mortality among patients after CVC removal for suspected CRBSI.
METHODS: A propensity score-matched cohort of patients with suspected CRBSI who underwent IRINC or no IRINC in a 32-bed ICU in a university hospital in China from January 2009 through April 2021. Catheter tip culture and clinical symptoms were used to identify patients with suspected CRBSI. The Kaplan-Meier method was used to analyse 30-day mortality before and after propensity score matching, and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality in the matched cohort were estimated with Cox proportional hazards models.
RESULTS: In total, 1,238 patients who had a CVC removed due to suspected CRBSI were identified. Among these patients, 877 (70.8%) underwent IRINC, and 361 (29.2%) did not. Among 682 propensity score-matched patients, IRINC was associated with an increased risk of 30-day mortality (HR, 1.481; 95% CI, 1.028 to 2.134) after multivariable, multilevel adjustment. Kaplan-Meier analysis found that IRINC was associated with the risk of mortality both before matching (P = 0.00096) and after matching (P = 0.018). A competing risk analysis confirmed the results of the propensity score-matched analysis. The attributable risk associated with bloodstream infection was not significantly different (HR, 1.081; 95% CI 0.964 to 1.213) among patients with suspected CRBSI in terms of 30-day mortality compared with that associated with other infections.
CONCLUSIONS: In this cohort study, IRINC was associated with higher 30-day mortality compared to delayed CVC or no CVC among patients with suspected CRBSI. A large-sample randomized controlled trial is needed to define the best management for CVC in cases of suspected CRBSI because IRINC may also be associated with noninfectious complications. Trial registration This study was registered with the China Clinical Trials Registry (URL: http://www.chictr.org.cn/index.aspx ) under the following registration number: ChiCTR1900022175.
参考来源
- Zhong Y, Deng L, Zhou L, et al. Association of immediate reinsertion of new catheters with subsequent mortality among patients with suspected catheter infection: a cohort study. Ann Intensive Care. 2022. PMID: 35524924. doi:10.1186/s13613-022-01014-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。